Adam Gaffney and our Zackary Berger write, “Single payer bills signal a new era in American healthcare politics”

Quick Read

Total costs of Kymriah and the 21 similar drugs in development — known as CAR T-cell therapies — will be far higher than many have imagined, reaching $1 million or more per patient, according to leading cancer experts. The next CAR T-cell drug could be approved as soon as November.

Quick Read

A federal judge in Texas invalidated four key patents for the dry-eye treatment Restasis on Monday, dealing a blow to its manufacturer, Allergan, which had sought to protect its patents by transferring them to a Native American tribe

Quick Read

Who will pay for it? And how?

Quick Read

“At first it’s cool, and then you realize, I’m filling some drugs that are for some pretty serious health problems as well. And these are the people that are running the country,” Pharmacist Mike Kim said, listing treatments for conditions like diabetes and Alzheimer’s. “It makes you kind of sit back and say, ‘Wow, they’re making the highest laws of the land and they might not even remember what happened yesterday.’”

Quick Read

In a deal similar to the one that turned the tide against AIDS, manufacturers and charities will make chemotherapy drugs available in six poor countries at steep discounts

Quick Read

For the first time, doctors have used gene therapy to stave off a fatal degenerative brain disease, an achievement that some experts had thought impossible. The key to making the therapy work? One of medicine’s greatest villains: HIV

Quick Read

With the country in the throes of an epidemic, communities across the nation are being forced to confront the harrowing, and often fatal, effects of opioid abuse. But solutions — such as creating intervention programs in Ohio, providing access to treatment in Alabama, or investing in prevention initiatives in Missouri — cost money

Quick Read